ALLOIMMUNITY IN AUTO IMMUNE DISEASE

自身免疫性疾病中的同种免疫

• 批准号: 6374187
• 负责人: J. Lee Nelson
• 金额: $ 47.3万
• 依托单位: FRED HUTCHINSON CANCER RESEARCH CENTER
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-08-01 至 2004-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6374187
• 关键词: DNA; autoantibody; autoimmune disorder; cell migration; cell population study; clinical research; disease /disorder etiology; flow cytometry; histocompatibility; histocompatibility typing; human genetic material tag; human subject; in situ hybridization; membrane permeability; pathologic process; placental transfer; pregnancy immunology; systemic lupus erythematosus; tissue /cell culture

Advances with molecular biological techniques have led to the appreciation that there is bi-directional traffic of cells during pregnancy. Fetal cells are found in maternal peripheral blood in the majority of first pregnancies and evidence for maternal cells has been found in over 40 percent of cord blood samples. Recently, the surprising observation was reported that fetal cells also can persist in maternal blood for decades after pregnancy completion. This observation raises the important question as to whether maternal cells also persist long-term in some offspring. It is well known that maternal cells engraft and persist in infants with severe combined immunodeficiency, but no previous study has investigated long-term persistence of maternal cells in normal individuals. In support of this probability, a cytogenetic study of male infants who received in utero transfusions from their mothers revealed some lymphocytes were XX at more than five years of age. In initial studies from our laboratory we report evidence for long-term persistence of maternal cells in some individuals up to 47 years after birth. Bi-directional traffic of cells during pregnancy, and long-term persistence of microchimerism in some individuals, when considered together with observations in experimental models and in human diseases characterized by chimerism (nonhost cells), led the investigator to propose the hypothesis that alloimmunity may contribute to some autoimmune disease. Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease for which a well-recognized experimental model involves the introduction of parental cells into F1 progeny. Some manifestations of SLE are also mimicked in human chronic graft-versus-host-disease that occurs after allogenic hematopoietic stem cell transplantation. The studies in this proposal are designed to investigate the hypothesis that maternal cells and/or DNA persist in some progeny and that maternal microchimerism contributes to the pathogenesis of some autoimmune diseases, specifically SLE. The proposed studies will investigate qualitative and quantitative aspects of persistent maternal microchimerism. To further address pathogenicity disease-affected tissues of SLE patients will be examined for maternal DNA and cells. The HLA- relationship of mother and her progeny will be investigated as a potential factor in the persistence and/or pathogenicity of persistent maternal microchimerism. The studies that are proposed may result in a new understanding of immunologic aspects and consequences of pregnancy. If persistent maternal microchimerism is involved in the pathogenesis of SLE new therapeutic modalities could be developed on this basis.

随着分子生物学技术的进步，人们认识到怀孕期间细胞的双向运输。 在大多数第一次怀孕的母亲外周血中发现了胎儿细胞，并且在超过40%的脐带血样本中发现了母体细胞的证据。最近，令人惊讶的观察报告说，胎儿细胞也可以在怀孕完成后在母体血液中持续数十年。 这一观察结果提出了一个重要的问题，即母体细胞是否也会在某些后代中长期存在。 众所周知，母体细胞在患有严重联合免疫缺陷的婴儿中移植并持续存在，但以前没有研究调查正常个体中母体细胞的长期持续存在。 为了支持这种可能性，一项对接受母亲子宫内输血的男婴进行的细胞遗传学研究显示，一些淋巴细胞在5岁以上时是XX。 在我们实验室的初步研究中，我们报告了一些个体在出生后长达47年的母体细胞长期存在的证据。怀孕期间细胞的双向运输，以及某些个体中微嵌合体的长期持续存在，当与实验模型和以嵌合体（非宿主细胞）为特征的人类疾病中的观察结果一起考虑时，导致研究者提出同种免疫可能导致某些自身免疫性疾病的假设。 系统性红斑狼疮（SLE）是一种原型自身免疫性疾病，其公认的实验模型涉及将亲本细胞引入F1子代。 SLE的一些表现也在同种异体造血干细胞移植后发生的人类慢性移植物抗宿主病中模仿。本研究旨在探讨母体细胞和/或DNA在某些子代中持续存在以及母体微嵌合体有助于某些自身免疫性疾病（特别是SLE）发病机制的假设。 拟议的研究将调查持续性母体微嵌合体的定性和定量方面。 为了进一步研究致病性，将检查SLE患者的疾病影响组织的母体DNA和细胞。 母亲及其后代的HLA关系将作为持续性母体微嵌合体的持续性和/或致病性的潜在因素进行研究。 所提出的研究可能会导致对免疫学方面和妊娠后果的新理解。 如果持续的母体微嵌合体参与SLE的发病机制，新的治疗方法可以在此基础上开发。